| 0.016 -0.018 (-53.49%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.02 | 1-year : | 0.03 |
| Resists | First : | 0.02 | Second : | 0.02 |
| Pivot price | 0.01  |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0.01 |
MA(20) : | 0.01 |
| MA(100) : | 0.05  |
MA(250) : | 0.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41 | D(3) : | 41 |
| RSI | RSI(14): 58.4 | |||
| 52-week | High : | 0.95 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LMDX ] has closed below upper band by 14.7%. Bollinger Bands are 80.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.03 - 0.03 | 0.03 - 0.03 |
| Low: | 0.01 - 0.02 | 0.02 - 0.02 |
| Close: | 0.02 - 0.02 | 0.02 - 0.02 |
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Fri, 12 Apr 2024
LumiraDx Limited (LMDX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Movies UK
Mon, 08 Jan 2024
Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket - Ainos (NASDAQ:AI - Benzinga
Mon, 08 Jan 2024
Why Is LumiraDx (LMDX) Stock Down 13% Today? - InvestorPlace
Fri, 05 Jan 2024
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th - Yahoo Finance
Tue, 02 Jan 2024
LumiraDx stock falls on M&A deal with Roche (NASDAQ:LMDX) - Seeking Alpha
Fri, 29 Dec 2023
LumiraDx to sell its point of care technology platform to Roche (NASDAQ:LMDX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 161 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 55.4 (%) |
| Held by Institutions | 25.2 (%) |
| Shares Short | 1,430 (K) |
| Shares Short P.Month | 3,500 (K) |
| EPS | -1.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.68 |
| Profit Margin | -267.2 % |
| Operating Margin | -231.5 % |
| Return on Assets (ttm) | -28.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -53 % |
| Gross Profit (p.s.) | 0.37 |
| Sales Per Share | 0.78 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -130 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | -0.03 |
| Price to Sales | 0.02 |
| Price to Cash Flow | -0.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|